GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.NRx Pharmaceuticals to Report Q1 2026 Results as CNS Pipeline Advances
NRx Pharmaceuticals will report Q1 2026 financials May 18, advancing its ketamine and D-cycloserine platforms for CNS disorders with breakthrough designations.
NRXPNRXPWclinical trialbiopharmaceutical